A new study highlighted by UT Southwestern shows that the FDA has expanded approval of belzutifan, a HIF-2α inhibitor, for use in earlier-stage kidney cancer settings. The expanded indication includes combination therapy with pembrolizumab as an adjuvant treatment following kidney cancer surgery, aiming to reduce the risk of recurrence in high-risk patients. Clinical trial data from the LITESPARK program demonstrated improved disease-free survival, reinforcing belzutifan’s growing role in transforming kidney cancer treatment strategies.